Moderna’s Revenue by Segment (2018-2022)

This statistic highlights Moderna’s Revenue by Segment, split between Collaboration Revenue, Grant Revenue, and Product Sales, reported on a quarterly basis.

Moderna’s Revenue by Segment

(All figures are in millions, except percentages)

Collaboration Revenue

Moderna Inc. has developed many medicines including strategic alliances with AstraZeneca, Merck & Co. Inc, and Vertex Pharmaceuticals Inc. discovering, developing, and commercializing potential mRNA medicines. The company made many collaborations including development services, research, licenses, and certain ways to obtain the development and commercialization rights and other related services and products. These all arrangements generate revenue through upfront fees, commercial milestone payments, royalties, licensing fees, option exercise fees, and other types of payments.

In Q3 2020, the segment earned $12 million, which rose to $19 million in Q3 2021, indicating a year-on-year growth of 58.33%. The company also made progress in the collaboration revenue segment and earned $19 million from Collaboration Revenue Segment (in Q3 2021) which contributed 0.4% to the total revenue of the company.

Grant Revenue

Grant Revenue Segment contributes 2.8% of the total revenue of Moderna Inc. generates moderate revenue through grants with various government-sponsored and private organizations. The company has established some contracts with the Biomedical Advanced Research and Development Authority (BARDA), the U.S. government’s Defense Advanced Research Projects Agency (DARPA), the Bill & Melinda Gates Foundation, and also from other organizations.

In Q3 2020, the segment earned $145 million which decreased to $140 million in Q3 2021, indicating a year-on-year fall of 3.44%. The company continued to earn revenue from the grant revenue segment even in the Coronavirus pandemic. In Q3 2021, Grant Segment generated $1.40 billion in revenue and contributed 2.8% to the total revenue of the Moderna company.

Product Sale

Product Sale is one of the highest-earning segments in Moderna Incorporation. it contributes around 95% to the total revenue of the company. This segment includes revenue generated through the sae of different products or medicines created by the company. it includes most famous called mRNA (Messenger RNA), this medicine performs the role in human body and transfer proteins in every cell where ever needed.

In Q2 2021, the segment earned $4197 million which increased to $4,810 million in Q3 2021, this segment contributed 96.8% in total revenue. This segment’s earning increased during the pandemic after receiving vaccine approval from the U.S. Food and Drug Administration FDA and Health Canada in December 2020. Moderna Inc. recently has seen its product sales explode after developing and winning government approval for an mRNA vaccine to protect against COVID-19.

About the Company

Moderna Inc. is a public and American company. It was founded in September 2010. It is a pharmaceutical and biotechnological based company situated in Cambridge. It operates as a clinical-stage biotechnology company. Moderna Incorporation focuses on the creation and development of the most successful medicine mRNA therapeutics and all the vaccines. Moderna Incorporation’s medicine MRNA is used for infectious, immuno-oncology, and cardiovascular diseases. The company has approximately 44 treatment, vaccine candidates, among which 21 vaccines had gone under the clinical trials.

The company has created an official website where customers can know about the schemes, new launches, and the latest information updated by the company. Moderna Incorporation deals with many customers around the globe and seeks for best services. The company’s mission is to develop medicines and cure the society and also prevent from diseases.

Did you like Moderna’s Revenue by Segment statistic?

Access more such KPI data points and segment financials on thousands of US stocks, with Business Quant.

You can get started here.